Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …

SARS-CoV-2 infection poses a major threat to the lungs and multiple other organs,
occasionally causing death. Until effective vaccines are developed to curb the pandemic, it …

Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …

Objectives The main aim of this study was to find the prevalence of mortality among
hospitalized COVID-19 infected patients and associated risk factors for death. Methods …

Clinical evidence indicates that the fatal outcome observed with severe acute respiratory
syndrome-coronavirus-2 infection often results from alveolar injury that impedes airway …

Background: The unpredictability of the progression of coronavirus disease 2019 (COVID-
19) may be attributed to the low precision of the tools used to predict the prognosis of this …

This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the
treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May …

Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of
severe COVID-19. The aim of this systematic review was to describe the rationale for the use …

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a
dysregulated hyperinflammatory response. Areas covered Authors review evidence on IL-6 …

A hyperinflammatory 'cytokine storm'state termed macrophage activation syndrome (MAS),
culminating from a complex interplay of genetics, immunodeficiency, infectious triggers and …